查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2032957

腎癌治療和診斷市場規模、佔有率、趨勢和預測：按成分、癌症類型、應用和地區分類，2026-2034 年

Kidney Cancer Therapeutics and Diagnostics Market Size, Share, Trends and Forecast by Component, Cancer Types, Application, and Region, 2026-2034
出版日期: | 出版商: IMARC | 英文 148 Pages | 商品交期: 2-3個工作天內

價格

2025年全球腎癌治療及診斷市場規模為57億美元。展望未來，IMARC Group預測，該市場將以5.67%的複合年成長率從2026年成長至2034年，到2034年達到95億美元。目前，北美市場主導地位，預計2025年市佔率將超過35.4%。腎癌發生率上升、人口老化以及政府支持措施是推動腎癌治療和診斷市場成長的主要因素。

全球腎癌病例數量不斷增加，對改進治療方法和診斷方法的需求日益迫切。人口老化以及吸煙、肥胖和高血壓等生活方式因素加劇了對腎癌藥物和診斷的需求。光是在美國，預計到2023年將有約15,000人死於腎癌，其中超過90%的成人腎癌為腎細胞癌（RCC）。這種情況凸顯了早期診斷對於預防死亡和疾病進展的重要性。儘管由於公眾意識的提高和定期體檢的普及，早期發現已變得越來越普遍，但病例數量的不斷增加仍然強調了創新的必要性。例如，影像技術和生物標記檢測的進步使得腎癌的早期發現成為可能，從而改善了治療效果。對更佳診斷和治療方法的需求正在推動該領域的研究和開發，並促進市場成長。腎癌治療和診斷藥物用於治療和診斷腎細胞癌（RCC）、良性腎腫瘤、威爾姆氏腫瘤、移行細胞癌、腎肉瘤、髓樣癌、多房囊性腎細胞癌以及黏液性小管癌和梭形細胞癌。

美國是北美腎癌市場的主要驅動力，佔89.60%的市佔率。 2024年，美國新增腎癌和腎盂癌病例81,610例，其中大多數患者年齡在65歲以上。老年人口不斷成長，他們容易患腎細胞癌和其他類型的腎癌，這推動了美國對能夠治療腫瘤、延長生存期並保護腎臟非癌症組織的治療方法和診斷方法的需求。此外，政府主導的各項提高公眾癌症意識的措施也為腎癌藥物和診斷市場帶來了良好的前景。推動美國市場成長的其他因素包括醫療保健產業的顯著進步、對研發活動的大量投資以探索潛在治療方法，以及機器人手術、遠端醫療和人工智慧等高科技治療方法的日益普及。

腎癌治療與診斷市場的發展趨勢：

腎癌發生率上升

腎癌治療和診斷市場佔有率不斷擴大的主要成長要素是全球腎癌發生率的上升。根據國際腎癌聯盟統計，每年約有43.1萬例新病例。隨著腎臟癌負擔的加重，對先進診斷和有效治療方法的需求日益成長，這仍將是一項嚴峻的挑戰。病例激增促使醫療系統積極採用世界領先的影像和分子診斷技術，以實現腎癌的早期準確分期。對標靶治療治療和免疫療法等新型創新治療方法的需求不斷成長，也要求在開發更個人化、更有效的治療方案方面取得重大進展。隨著全球腎癌發病率的上升，隨著能夠改善患者預後的創新療法和解決方案的不斷湧現，腎癌市場有望持續成長。

診斷和治療技術的進步

基於生物標記的診斷、液態生物檢體以及PET/ 電腦斷層掃描等先進影像技術的顯著進步提高了腎癌的早期檢出率。精準的診斷和合理的治療方案能夠改善患者的預後。標靶治療、免疫療法（例如免疫查核點抑制劑）以及個人化醫療方法正在革新治療策略，從而推動腎癌治療和診斷市場的成長。例如，加拿大衛生署於2022年10月核准了KEYTRUDA上市。這項批准意義重大，因為KEYTRUDA當時獲準用於輔助單藥治療，適用於腎切除術後或腎切除術合併轉移灶切除術後復發風險為中高或高風險的成人腎細胞癌（RCC）患者。這些核准進一步加速了免疫療法在腎癌治療中的應用，形成了一個良性循環，進一步增加了對先進治療方法的需求，並推動了腎癌治療和診斷市場的成長。

擴大投資和研發活動

根據腎癌（RNC）治療和診斷市場的預測，腫瘤學領域的大量資金投入和研究活動正在推動RNC新治療方法，從而刺激市場成長。在這方面，美國國家癌症研究所（NCI）在為RNC研究提供大量資金方面發揮著至關重要的作用，這些資金推動了創新，並最終促成了下一代診斷和治療方案的推出。公共和私人投資舉措也促進了研發投入的增加，進一步推動了市場成長。例如，2022年9月，威爾康奈爾醫學院獲得了美國國防部腎癌研究計畫提供的為期三年、金額為100萬美元的津貼。該計畫正在研究ATF4蛋白在透明細胞腎細胞癌（ccRCC）中的功能，特別是其在突破性治療方法的潛力。此類資助有助於識別新的生物標記、標靶化新治療方法以及改進診斷流程，所有這些都將有助於更好地管理RNC患者，並促進市場上治療方法和診斷技術的持續發展。

目錄

第1章：序言

第2章：調查方法

  • 調查目的
  • 相關利益者
  • 數據來源
    • 主要訊息
    • 次要訊息
  • 市場估值
    • 自下而上的方法
    • 自上而下的方法
  • 預測方法

第3章執行摘要

第4章：引言

第5章：全球腎癌治療與診斷市場

  • 市場概覽
  • 市場表現
  • 新冠疫情的影響
  • 市場預測

第6章 市場區隔：依組件分類

  • 製藥
    • 主要部分
      • 藥品：依治療領域分類
        • 標靶治療
        • 免疫療法
        • 其他
      • 藥物：依藥理學分類
        • 血管新生抑制劑
        • mTOR抑制劑
        • 單株抗體
        • 細胞激素免疫療法（II-2）
  • 診斷
    • 主要部分
      • 影像檢查
      • 切片檢查
      • 驗血
      • 其他

第7章 市場區隔：依癌症類型分類

  • 透明細胞腎細胞癌
  • 乳頭狀腎細胞癌
  • 無色素性腎細胞癌
  • 移行細胞癌
  • 其他

第8章 市場區隔：依應用領域分類

  • 醫院
  • 藥物研究所
  • 基因組學研究所
  • 其他

第9章 市場區隔：依地區分類

  • 北美洲
    • 美國
    • 加拿大
  • 亞太地區
    • 中國
    • 日本
    • 印度
    • 韓國
    • 澳洲
    • 印尼
    • 其他
  • 歐洲
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙
    • 俄羅斯
    • 其他
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 其他
  • 中東和非洲

第10章：促進、抑制與機遇

第11章：價值鏈分析

第12章：波特五力分析

第13章：價格分析

第14章 競爭格局

  • 市場結構
  • 大公司
  • 主要公司簡介
    • Bristol-Myers Squibb Company
    • Exelixis Inc.
    • Genentech Inc.（Roche Holding AG）
    • Novartis AG
    • Pfizer Inc.
Product Code: SR112026A7528

The global kidney cancer therapeutics and diagnostics market size was valued at USD 5.7 Billion in 2025. Looking forward, IMARC Group estimates the market to reach USD 9.5 Billion by 2034, exhibiting a CAGR of 5.67% during 2026-2034. North America currently dominates the market, holding a market share of over 35.4% in 2025. The rising incidences of kidney cancer, increasing geriatric population, and favorable initiatives by several governments represent some of the key factors driving the kidney cancer therapeutics and diagnostics market share.

Kidney cancer cases are increasing globally, creating a significant need for improved treatment and diagnostic options. Factors like aging populations and lifestyle habits such as smoking, obesity, and high blood pressure (BP) contribute to boosting the kidney cancer therapeutics and diagnostics market demand. In the United States alone, kidney cancer caused nearly 15,000 deaths in 2023 and over 90 percent of adult kidney cancers were renal cell carcinoma (RCC). This has created the need or early diagnosis to prevent deaths and spread of the disease. Early detection has also become more common due to increased awareness and routine health check-ups, but the growing number of cases highlights the need for innovation. For instance, advancements in imaging technology and biomarker testing are helping detect kidney cancer at earlier stages, which improves treatment outcomes. This demand for better diagnostic and therapeutic options drives market growth by encouraging research and development in this space. Kidney cancer therapeutics and diagnostics are employed to treat and diagnose renal cell carcinoma (RCC), benign tumors of the kidney, Wilms tumors, transitional cell carcinoma, renal sarcoma, medullary carcinoma, multilocular cystic RCC, and mucinous tubular and spindle cell carcinoma.

The United States is a major market disruptor with 89.60% in North America. In the year 2024, 81,610 new cases of kidney and renal pelvis cancer in the U.S. were recorded with the majority occurring in individuals aged 65 and older. The increasing elderly population, with its susceptibility to renal cell carcinoma and other kidney cancer types, is helping drive demand for therapies and diagnostics that can treat tumors, extend survival, and preserve the noncancerous parts of the kidney in the country. Moreover, the implementation of various government initiatives to spread awareness regarding cancer is creating a positive kidney cancer therapeutics and diagnostics market outlook. Other factors that push the growth in the United Sates include major advancements in the healthcare sector, significant investment in R&D activities to explore potential treatment options, and the growing acceptance of high-tech methods of treatments like robotic surgery, telemedicine, and artificial intelligence.

KIDNEY CANCER THERAPEUTICS AND DIAGNOSTICS MARKET TRENDS:

Rising Prevalence of Kidney Cancer

A key growth driver for the kidney cancer therapeutics and diagnostics market share is the rising global incidence of kidney cancer. The International Kidney Cancer Coalition reported about 431,000 new cases every year. With the rising burden of the disease, the increasing demand for advanced diagnostic and effective therapeutic options will remain a crucial challenge. This surge is thus motivating the health care systems to seek some of the world's recent cutting-edge technologies in diagnosis imaging techniques and in molecular diagnostics intended for early and proper staging in kidney cancer cases. Growing demands for new and innovative therapies-such as targeted treatments and immunotherapies-in turn call for tremendous improvement in the formulation of more tailor-made and highly effective treatment protocols. With the increased incidence of kidney cancer worldwide, the market is therefore bound to continue growing, with innovation and solutions availed on the market to improve patient outcomes.

Advancements in Diagnostic and Therapeutic Technologies

Significant developments in biomarker-based diagnostics, liquid biopsies, and advanced imaging technologies such as PET/CT scans have improved early detection rates for kidney cancer. Accurate diagnosis and appropriate planning lead to better outcomes for patients. Targeted therapies, immunotherapies like immune checkpoint inhibitors, and personalized medicine approaches are now revolutionizing the treatment strategies that are boosting the kidney cancer therapeutics and diagnostics market growth. One in point includes the approval made by Health Canada in October 2022 to KEYTRUDA. This marks the significance as at that point, KEYTRUDA was deemed as a monotherapy for the adjuvant treatment of adults with RCC at intermediate-high or high risk of either recurrence after nephrectomy or after nephrectomy and resection of metastatic lesions. The approvals further add up to the rising use of immunotherapy for kidney cancer treatments, which has created a cycle of further increasing demand for the advanced forms of treatment and fueling growth in the market for therapeutics and diagnostics of kidney cancer.

Increasing Investments and Research Initiatives

As per the kidney cancer therapeutics and diagnostics market forecast, significant funding and research activities in oncology are driving new treatments for kidney cancer, thereby propelling the growth of the market. In this regard, the National Cancer Institute is a significant player that provides substantial funds for kidney cancer research, an aspect that drives innovation and the subsequent introduction of the next-generation diagnostic and therapeutic solutions. Public and private sector investment initiatives have also helped promote investments in research and development, which further promote market growth. For example, in September 2022, Weill Cornell Medicine received a USD 1 million three-year grant from the Department of Defense's Kidney Cancer Research Program. The body is researching the function of the ATF4 protein in clear cell renal cell carcinoma (ccRCC), especially about its possible revolutionary therapy. This type of funding will help recognize novel biomarkers, target new therapies, and refine diagnostic processes; all lead to better managements of the kidney cancer patients, which encourage continuous development within therapeutics and diagnostics in the market.

KIDNEY CANCER THERAPEUTICS AND DIAGNOSTICS INDUSTRY SEGMENTATION:

Analysis by Component:

  • Drugs
    • Drugs by Therapeutic Class Targeted Therapy Immunotherapy Others
    • Drugs by Pharmacologic Class Angiogenesis Inhibitors mTOR Inhibitors Monoclonal Antibodies Cytokine Immunotherapy (II-2)
  • Diagnostics
    • Imaging Test
    • Biopsy
    • Blood Test
    • Others
  • Drugs by Therapeutic Class
    • Targeted Therapy
    • Immunotherapy
    • Others
  • Drugs by Pharmacologic Class
    • Angiogenesis Inhibitors
    • mTOR Inhibitors
    • Monoclonal Antibodies
    • Cytokine Immunotherapy (II-2)

Drugs lead the market with approximately 84.3% of market share in 2025. The supremacy of drugs in the market has developed primarily due to their high efficacy and potential side-effect-free aspects as demanded by the targeted therapies and immunotherapies. The relevant drugs, useful in targeted therapy are TKIs like sunitinib and pazopanib, while some examples of immunotherapy include immune checkpoint inhibitors pembrolizumab and nivolumab. The spreading consumption of these drugs is associated with their superior efficacy and reduced side effects as compared to conventional chemotherapies. The incessant introduction of new drugs and combination therapies through intensive R&D activities has fueled the segment's growth. The drugs segment is thus an important growth driver for the market given the increasing incidence of kidney cancer and the need for personalized and oriented medicines.

Analysis by Cancer Types:

  • Clear Cell RCC
  • Papillary RCC
  • Chromophobe RCC
  • Transitional Cell Carcinoma

Clear cell RCC leads the market with around 66.3% of market share in 2025. This cancer type is characterized by the presence of clear cells, which have a distinct appearance due to their high lipid and glycogen content. It is often diagnosed at an advanced stage and is associated with a poor prognosis if not treated promptly. The large share of the clear cell RCC segment in the market is driven by the increasing prevalence of this cancer type, advancements in targeted therapies and immunotherapy, and the growing focus on early detection and personalized treatment options.

Analysis by Application:

  • Hospitals
  • Pharmaceutical Labs
  • Genomic Laboratories

Hospital leads the market with a total market share of approximately 40.0% in 2025. The hospital-based market is dominated as they have the proper infrastructure facilities for the diagnosis and treatment processes of kidney cancer. They are well-equipped with extensive diagnostics, including imaging techniques and biopsies, which are mandatory for the proper staging and treatment of this cancer. Furthermore, the existence of specific oncology units in hospitals also implies a variety of treatments available, such as surgery, radiation therapy, targeted therapies, and immunotherapy among others. Multidisciplinary care teams consisting of oncologists, radiologists, and surgeons are present; such teams make a hospital's role in the management of kidney cancer more potent. With the increasing incidence of kidney cancer, hospitals are the primary healthcare setting for both initial diagnosis and ongoing treatment, thereby driving the largest share of this segment in the market.

Regional Analysis:

  • North America
    • United States
    • Canada
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Indonesia
    • Others
  • Europe
    • Germany
    • France
    • United Kingdom
    • Italy
    • Spain
    • Russia
    • Others
  • Latin America
    • Brazil
    • Mexico
    • Others
  • Middle East and Africa

In 2025, North America held the highest market share of 35.4%. The U.S. takes a lead in this market for a number of reasons that include the high prevalence of kidney cancer, cutting-edge infrastructural health facilities, and significant research development and manufacturing investments. The region is rich in healthcare infrastructural systems, advanced diagnostic technologies, and access to a variety of treatment modalities; some of them being targeted therapy and immunotherapy that provide value to patients. In light of this, North America has a strong pipeline for new therapies and diagnostic tools from various pharmaceutical companies and academic institutions to guarantee their place in the market. The huge awareness growth and initiative have made North America, with numerous early detection programs, to be the largest market for kidney cancer therapeutics and diagnostics.

KEY REGIONAL TAKEAWAYS:

UNITED STATES KIDNEY CANCER THERAPEUTICS AND DIAGNOSTICS MARKET ANALYSIS

The United States is leading the market with 89.60% share in North America. The increasing prevalence of kidney cancer in America is a significant cause of the kidney cancer therapeutics and diagnostics market growth. The American Cancer Society's 2022 update reports approximately 79,000 new diagnoses of kidney cancer in the U.S. by the end of 2022. This growing incident rate has increased the demand for efficient diagnosis and better treatment options, such as targeted therapies and immunotherapies. An additional number of patient diagnostics increases the demands for early diagnostic techniques, molecular diagnostics, and imaging technologies. Furthermore, in light of developing personalized medicine as well as implementing new treatments is fueling rapid growth in this market. Moving forward, expanding research, alongside increased awareness over kidney cancer will provide an impetus to the overall market for both therapeutics as well as diagnostics. This trend is further supported by ongoing investments in healthcare infrastructure and oncology services across the country.

EUROPE KIDNEY CANCER THERAPEUTICS AND DIAGNOSTICS MARKET ANALYSIS

One of the main growth drivers of the kidney cancer therapeutics and diagnostics market in Europe is the rising incidence of renal cell carcinoma (RCC). The world witnessed an estimated 431,288 new cases of RCC in 2020, while in the European region, there were an estimated 138,611 cases, according to Euroweb. Therefore, the rising number of diagnoses is driving the demand for early detection as well as effective treatment options. The diagnostic tools in Europe are experiencing great leap ahead in terms of imaging technologies and biomarkers-assisted testing to achieve a better early diagnosis of RCC. Moreover, the heightened interest in personal therapies such as targeted medicines and immunotherapy has driven the market since healthcare providers have a preference for such treatments, which can more effectively impact patients suffering from RCC. Additionally, a strong health care infrastructure in Europe and continued investments in cancer research and clinical trials also help support the growth of the therapeutics and diagnostics market. With the increasing incidence of RCC, there will be a steady demand for innovative treatment options and diagnostic solutions.

ASIA PACIFIC KIDNEY CANCER THERAPEUTICS AND DIAGNOSTICS MARKET ANALYSIS

The rapidly increasing incidence of kidney cancer in China has been an important growth factor driving the Asia-Pacific market of kidney cancer therapeutics and diagnostics. According to the NIH, in 2019, there were 59,827 new cases, 23,954 deaths, and 642,799 DALYs for kidney cancer in China. This is indicative of the increasing burden of kidney cancer and thus the increasing need for better diagnostic tools and treatment options. China is currently coming to terms with a rapidly increasing number of people being diagnosed with kidney cancer, for which early detection and targeted treatment and immunotherapy are highly in demand. Furthermore, the development of healthcare infrastructure and investments by the government for cancer treatment at a rapid scale are augmenting the market. Driven by the growing need to address the rising prevalence of kidney cancer in the region, the Asia-Pacific kidney cancer therapeutics and diagnostics market has focused increasingly on improving access to treatment and enhancing treatment outcomes.

LATIN AMERICA KIDNEY CANCER THERAPEUTICS AND DIAGNOSTICS MARKET ANALYSIS

The aging population is a growth driver for the therapeutics and diagnostics market for kidney cancer in the region of Latin America and the Caribbean. There were 88.6 million people aged 60 years and more living in the region in 2022. This proportion comprised 13.4% of the total population, as cited by CEPAL. Such a proportion would increase to 16.5% by 2030. Age being one of the primary risk factors for kidney cancer, the geriatric population rising in Latin America also increases cases of kidney cancer. This population necessitates not only early detection but also treatment; it is putting further pressure on adopting advanced diagnostics and novel treatments like targeted and immunotherapies in Latin America. As healthcare organizations adjust to the population shift of increasingly aged citizens, this Latin America market for the therapy and diagnosis of kidney cancer can look forward to explosive growth over time, where such patients should improve.

MIDDLE EAST AND AFRICA KIDNEY CANCER THERAPEUTICS AND DIAGNOSTICS MARKET ANALYSIS

One of the biggest growth drivers of the market for kidney cancer therapeutics and diagnostics remains the increasing incidence of kidney cancer in the Middle East and North Africa region. Industry reports indicate the rise of age-standardized incidence rate of kidney cancer in 17 countries of MENA in the period from 1990 to 2019. The high increase was noted in Saudi Arabia, Oman, and Lebanon-which are the most significant burdens faced by the region. Several factors have influenced the increase in cases of kidney cancer. These include changed lifestyle activities and rapid urbanization, which can be associated with increased risk factors in recent times, for example, smoking, obesity, and hypertension. Such an increase in incidence in cases of kidney cancer stimulates both early diagnosis and advanced treatments. This has led to increased adoption of high-end diagnostic technologies, including molecular imaging and biopsy techniques, as well as new therapies, such as targeted and immunotherapies, by healthcare systems within the region.

COMPETITIVE LANDSCAPE:

As per the kidney cancer therapeutics and diagnostics market trends, key players in the market are actively engaged in advancing treatments, enhancing diagnostics, and expanding their product portfolios to cater to the growing demand. Pharmaceutical companies are focusing on the development of targeted therapies and immunotherapies, such as immune checkpoint inhibitors and tyrosine kinase inhibitors, to improve patient outcomes in advanced stages of kidney cancer. These companies are also involved in conducting clinical trials to introduce novel drugs that target specific molecular pathways associated with renal cell carcinoma. Additionally, diagnostics companies are enhancing imaging technologies and introducing non-invasive diagnostic tools for early detection, which can significantly improve prognosis and treatment success. Strategic collaborations, partnerships, and acquisitions are common in the market, as companies aim to leverage each other's expertise in cancer research and technological innovation. With the rising demand for personalized medicine, these players are also focusing on biomarkers and genetic profiling to provide tailored treatment plans for kidney cancer patients.

The report provides a comprehensive analysis of the competitive landscape in the kidney cancer therapeutics and diagnostics market with detailed profiles of all major companies, including:

  • Bristol-Myers Squibb Company
  • Exelixis Inc.
  • Genentech Inc. (Roche Holding AG)
  • Novartis AG
  • Pfizer Inc

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global Kidney Cancer Therapeutics and Diagnostics Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Forecast

6 Market Breakup by Component

  • 6.1 Drugs
    • 6.1.1 Market Trends
    • 6.1.2 Key Segments
      • 6.1.2.1 Drugs by Therapeutic Class
        • 6.1.2.1.1 Targeted Therapy
        • 6.1.2.1.2 Immunotherapy
        • 6.1.2.1.3 Others
      • 6.1.2.2 Drugs by Pharmacologic Class
        • 6.1.2.2.1 Angiogenesis Inhibitors
        • 6.1.2.2.2 mTOR Inhibitors
        • 6.1.2.2.3 Monoclonal Antibodies
        • 6.1.2.2.4 Cytokine Immunotherapy (II-2)
    • 6.1.3 Market Forecast
  • 6.2 Diagnostics
    • 6.2.1 Market Trends
    • 6.2.2 Key Segments
      • 6.2.2.1 Imaging Test
      • 6.2.2.2 Biopsy
      • 6.2.2.3 Blood Test
      • 6.2.2.4 Others
    • 6.2.3 Market Forecast

7 Market Breakup by Cancer Types

  • 7.1 Clear Cell RCC
    • 7.1.1 Market Trends
    • 7.1.2 Market Forecast
  • 7.2 Papillary RCC
    • 7.2.1 Market Trends
    • 7.2.2 Market Forecast
  • 7.3 Chromophobe RCC
    • 7.3.1 Market Trends
    • 7.3.2 Market Forecast
  • 7.4 Transitional Cell Carcinoma
    • 7.4.1 Market Trends
    • 7.4.2 Market Forecast
  • 7.5 Others
    • 7.5.1 Market Trends
    • 7.5.2 Market Forecast

8 Market Breakup by Application

  • 8.1 Hospitals
    • 8.1.1 Market Trends
    • 8.1.2 Market Forecast
  • 8.2 Pharmaceutical Labs
    • 8.2.1 Market Trends
    • 8.2.2 Market Forecast
  • 8.3 Genomics Laboratories
    • 8.3.1 Market Trends
    • 8.3.2 Market Forecast
  • 8.4 Others
    • 8.4.1 Market Trends
    • 8.4.2 Market Forecast

9 Market Breakup by Region

  • 9.1 North America
    • 9.1.1 United States
      • 9.1.1.1 Market Trends
      • 9.1.1.2 Market Forecast
    • 9.1.2 Canada
      • 9.1.2.1 Market Trends
      • 9.1.2.2 Market Forecast
  • 9.2 Asia-Pacific
    • 9.2.1 China
      • 9.2.1.1 Market Trends
      • 9.2.1.2 Market Forecast
    • 9.2.2 Japan
      • 9.2.2.1 Market Trends
      • 9.2.2.2 Market Forecast
    • 9.2.3 India
      • 9.2.3.1 Market Trends
      • 9.2.3.2 Market Forecast
    • 9.2.4 South Korea
      • 9.2.4.1 Market Trends
      • 9.2.4.2 Market Forecast
    • 9.2.5 Australia
      • 9.2.5.1 Market Trends
      • 9.2.5.2 Market Forecast
    • 9.2.6 Indonesia
      • 9.2.6.1 Market Trends
      • 9.2.6.2 Market Forecast
    • 9.2.7 Others
      • 9.2.7.1 Market Trends
      • 9.2.7.2 Market Forecast
  • 9.3 Europe
    • 9.3.1 Germany
      • 9.3.1.1 Market Trends
      • 9.3.1.2 Market Forecast
    • 9.3.2 France
      • 9.3.2.1 Market Trends
      • 9.3.2.2 Market Forecast
    • 9.3.3 United Kingdom
      • 9.3.3.1 Market Trends
      • 9.3.3.2 Market Forecast
    • 9.3.4 Italy
      • 9.3.4.1 Market Trends
      • 9.3.4.2 Market Forecast
    • 9.3.5 Spain
      • 9.3.5.1 Market Trends
      • 9.3.5.2 Market Forecast
    • 9.3.6 Russia
      • 9.3.6.1 Market Trends
      • 9.3.6.2 Market Forecast
    • 9.3.7 Others
      • 9.3.7.1 Market Trends
      • 9.3.7.2 Market Forecast
  • 9.4 Latin America
    • 9.4.1 Brazil
      • 9.4.1.1 Market Trends
      • 9.4.1.2 Market Forecast
    • 9.4.2 Mexico
      • 9.4.2.1 Market Trends
      • 9.4.2.2 Market Forecast
    • 9.4.3 Others
      • 9.4.3.1 Market Trends
      • 9.4.3.2 Market Forecast
  • 9.5 Middle East and Africa
    • 9.5.1 Market Trends
    • 9.5.2 Market Breakup by Country
    • 9.5.3 Market Forecast

10 Drivers, Restraints, and Opportunities

  • 10.1 Overview
  • 10.2 Drivers
  • 10.3 Restraints
  • 10.4 Opportunities

11 Value Chain Analysis

12 Porters Five Forces Analysis

  • 12.1 Overview
  • 12.2 Bargaining Power of Buyers
  • 12.3 Bargaining Power of Suppliers
  • 12.4 Degree of Competition
  • 12.5 Threat of New Entrants
  • 12.6 Threat of Substitutes

13 Price Analysis

14 Competitive Landscape

  • 14.1 Market Structure
  • 14.2 Key Players
  • 14.3 Profiles of Key Players
    • 14.3.1 Bristol-Myers Squibb Company
      • 14.3.1.1 Company Overview
      • 14.3.1.2 Product Portfolio
      • 14.3.1.3 Financials
      • 14.3.1.4 SWOT Analysis
    • 14.3.2 Exelixis Inc.
      • 14.3.2.1 Company Overview
      • 14.3.2.2 Product Portfolio
      • 14.3.2.3 Financials
      • 14.3.2.4 SWOT Analysis
    • 14.3.3 Genentech Inc. (Roche Holding AG)
      • 14.3.3.1 Company Overview
      • 14.3.3.2 Product Portfolio
      • 14.3.3.3 SWOT Analysis
    • 14.3.4 Novartis AG
      • 14.3.4.1 Company Overview
      • 14.3.4.2 Product Portfolio
      • 14.3.4.3 Financials
      • 14.3.4.4 SWOT Analysis
    • 14.3.5 Pfizer Inc.
      • 14.3.5.1 Company Overview
      • 14.3.5.2 Product Portfolio
      • 14.3.5.3 Financials
      • 14.3.5.4 SWOT Analysis

List of Figures

  • Figure 1: Global: Kidney Cancer Therapeutics and Diagnostics Market: Major Drivers and Challenges
  • Figure 2: Global: Kidney Cancer Therapeutics and Diagnostics Market: Sales Value (in Billion USD), 2020-2025
  • Figure 3: Global: Kidney Cancer Therapeutics and Diagnostics Market Forecast: Sales Value (in Billion USD), 2026-2034
  • Figure 4: Global: Kidney Cancer Therapeutics and Diagnostics Market: Breakup by Component (in %), 2025
  • Figure 5: Global: Kidney Cancer Therapeutics and Diagnostics Market: Breakup by Cancer Types (in %), 2025
  • Figure 6: Global: Kidney Cancer Therapeutics and Diagnostics Market: Breakup by Application (in %), 2025
  • Figure 7: Global: Kidney Cancer Therapeutics and Diagnostics Market: Breakup by Region (in %), 2025
  • Figure 8: Global: Kidney Cancer Therapeutics and Diagnostics (Drugs) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 9: Global: Kidney Cancer Therapeutics and Diagnostics (Drugs) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 10: Global: Kidney Cancer Therapeutics and Diagnostics (Diagnostics) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 11: Global: Kidney Cancer Therapeutics and Diagnostics (Diagnostics) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 12: Global: Kidney Cancer Therapeutics and Diagnostics (Clear Cell RCC) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 13: Global: Kidney Cancer Therapeutics and Diagnostics (Clear Cell RCC) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 14: Global: Kidney Cancer Therapeutics and Diagnostics (Papillary RCC) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 15: Global: Kidney Cancer Therapeutics and Diagnostics (Papillary RCC) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 16: Global: Kidney Cancer Therapeutics and Diagnostics (Chromophobe RCC) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 17: Global: Kidney Cancer Therapeutics and Diagnostics (Chromophobe RCC) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 18: Global: Kidney Cancer Therapeutics and Diagnostics (Transitional Cell Carcinoma) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 19: Global: Kidney Cancer Therapeutics and Diagnostics (Transitional Cell Carcinoma) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 20: Global: Kidney Cancer Therapeutics and Diagnostics (Other Applications) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 21: Global: Kidney Cancer Therapeutics and Diagnostics (Other Applications) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 22: Global: Kidney Cancer Therapeutics and Diagnostics (Hospitals) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 23: Global: Kidney Cancer Therapeutics and Diagnostics (Hospitals) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 24: Global: Kidney Cancer Therapeutics and Diagnostics (Pharmaceutical Labs) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 25: Global: Kidney Cancer Therapeutics and Diagnostics (Pharmaceutical Labs) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 26: Global: Kidney Cancer Therapeutics and Diagnostics (Genomics Laboratories) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 27: Global: Kidney Cancer Therapeutics and Diagnostics (Genomics Laboratories) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 28: Global: Kidney Cancer Therapeutics and Diagnostics (Other Applications) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 29: Global: Kidney Cancer Therapeutics and Diagnostics (Other Applications) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 30: North America: Kidney Cancer Therapeutics and Diagnostics Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 31: North America: Kidney Cancer Therapeutics and Diagnostics Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 32: United States: Kidney Cancer Therapeutics and Diagnostics Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 33: United States: Kidney Cancer Therapeutics and Diagnostics Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 34: Canada: Kidney Cancer Therapeutics and Diagnostics Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 35: Canada: Kidney Cancer Therapeutics and Diagnostics Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 36: Asia-Pacific: Kidney Cancer Therapeutics and Diagnostics Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 37: Asia-Pacific: Kidney Cancer Therapeutics and Diagnostics Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 38: China: Kidney Cancer Therapeutics and Diagnostics Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 39: China: Kidney Cancer Therapeutics and Diagnostics Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 40: Japan: Kidney Cancer Therapeutics and Diagnostics Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 41: Japan: Kidney Cancer Therapeutics and Diagnostics Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 42: India: Kidney Cancer Therapeutics and Diagnostics Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 43: India: Kidney Cancer Therapeutics and Diagnostics Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 44: South Korea: Kidney Cancer Therapeutics and Diagnostics Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 45: South Korea: Kidney Cancer Therapeutics and Diagnostics Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 46: Australia: Kidney Cancer Therapeutics and Diagnostics Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 47: Australia: Kidney Cancer Therapeutics and Diagnostics Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 48: Indonesia: Kidney Cancer Therapeutics and Diagnostics Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 49: Indonesia: Kidney Cancer Therapeutics and Diagnostics Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 50: Others: Kidney Cancer Therapeutics and Diagnostics Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 51: Others: Kidney Cancer Therapeutics and Diagnostics Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 52: Europe: Kidney Cancer Therapeutics and Diagnostics Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 53: Europe: Kidney Cancer Therapeutics and Diagnostics Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 54: Germany: Kidney Cancer Therapeutics and Diagnostics Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 55: Germany: Kidney Cancer Therapeutics and Diagnostics Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 56: France: Kidney Cancer Therapeutics and Diagnostics Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 57: France: Kidney Cancer Therapeutics and Diagnostics Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 58: United Kingdom: Kidney Cancer Therapeutics and Diagnostics Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 59: United Kingdom: Kidney Cancer Therapeutics and Diagnostics Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 60: Italy: Kidney Cancer Therapeutics and Diagnostics Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 61: Italy: Kidney Cancer Therapeutics and Diagnostics Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 62: Spain: Kidney Cancer Therapeutics and Diagnostics Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 63: Spain: Kidney Cancer Therapeutics and Diagnostics Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 64: Russia: Kidney Cancer Therapeutics and Diagnostics Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 65: Russia: Kidney Cancer Therapeutics and Diagnostics Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 66: Others: Kidney Cancer Therapeutics and Diagnostics Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 67: Others: Kidney Cancer Therapeutics and Diagnostics Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 68: Latin America: Kidney Cancer Therapeutics and Diagnostics Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 69: Latin America: Kidney Cancer Therapeutics and Diagnostics Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 70: Brazil: Kidney Cancer Therapeutics and Diagnostics Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 71: Brazil: Kidney Cancer Therapeutics and Diagnostics Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 72: Mexico: Kidney Cancer Therapeutics and Diagnostics Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 73: Mexico: Kidney Cancer Therapeutics and Diagnostics Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 74: Others: Kidney Cancer Therapeutics and Diagnostics Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 75: Others: Kidney Cancer Therapeutics and Diagnostics Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 76: Middle East and Africa: Kidney Cancer Therapeutics and Diagnostics Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 77: Middle East and Africa: Kidney Cancer Therapeutics and Diagnostics Market: Breakup by Country (in %), 2025
  • Figure 78: Middle East and Africa: Kidney Cancer Therapeutics and Diagnostics Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 79: Global: Kidney Cancer Therapeutics and Diagnostics Industry: Drivers, Restraints, and Opportunities
  • Figure 80: Global: Kidney Cancer Therapeutics and Diagnostics Industry: Value Chain Analysis
  • Figure 81: Global: Kidney Cancer Therapeutics and Diagnostics Industry: Porter's Five Forces Analysis

List of Tables

  • Table 1: Global: Kidney Cancer Therapeutics and Diagnostics Market: Key Industry Highlights, 2025 & 2034
  • Table 2: Global: Kidney Cancer Therapeutics and Diagnostics Market Forecast: Breakup by Component (in Million USD), 2026-2034
  • Table 3: Global: Kidney Cancer Therapeutics and Diagnostics Market Forecast: Breakup by Cancer Types (in Million USD), 2026-2034
  • Table 4: Global: Kidney Cancer Therapeutics and Diagnostics Market Forecast: Breakup by Application (in Million USD), 2026-2034
  • Table 5: Global: Kidney Cancer Therapeutics and Diagnostics Market Forecast: Breakup by Region (in Million USD), 2026-2034
  • Table 6: Global: Kidney Cancer Therapeutics and Diagnostics Market: Competitive Structure
  • Table 7: Global: Kidney Cancer Therapeutics and Diagnostics Market: Key Players